Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery

Launched by KRISTEN BAN · Oct 23, 2024

Keywords

ClinConnect Summary

This clinical trial is studying whether giving a medication called tranexamic acid (TXA) before major colorectal surgery can help reduce bleeding during and after the operation. Researchers will compare patients who receive TXA to those who do not, to see if TXA can lower the amount of blood loss and complications related to bleeding, such as needing a blood transfusion or further surgery. They will also check if using TXA increases the risk of serious blood clots or other complications after surgery.

To participate in this trial, you must be an adult aged 18 or older and scheduled for an inpatient colorectal surgery. However, there are some exclusions, such as if you have severe kidney problems or a history of certain blood clotting disorders. If you join the study, you can expect to receive the TXA medication through an IV at the start and end of your surgery. This trial is not yet recruiting participants, but it aims to gather important information that could improve surgical care for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adults 18 years or older
• • 2. Undergoing elective or non-elective inpatient abdominal and pelvic colorectal surgery
• Exclusion Criteria:
• • 1. Creatinine clearance less than 30 mL/minute
• • 2. Long-term dialysis
• • 3. Known defective color vision (color blind)
• • 4. Pregnancy
• • 5. History of venous or arterial thromboembolism, or active thromboembolic disease
• • 6. Disseminated intravascular coagulation (DIC) - clinically suspected and/or confirmed by platelet count on CBC, fibrinogen, INR and PTT.